Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00335140 · OUTCOME

Complete Response Rate - Locally Reviewed

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma · Source last updated 2023-07-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
For the primary endpoint, complete response will be based on disease status at three weeks post the end of therapy (week 17).

What was measured

Assessed by the ECOG-ACRIN data manager based upon local review of images and data sent by the local sites. Treatment response was determined by calculating the sum of the maximal cross section in 2 separate axes using enhancing lesion(s) on CT or MRI imaging. The same imaging modality was to be used throughout assessment. Complete response was defined as the disappearance of all contrast enhancing tumor size on CT or MRI, patient was off all glucocorticoids, and resolution of all meningeal and vitreous involvement if present. Response must have lasted at least 4 weeks.

Analysis population: Eligible, treated patients

Groups in this outcome

Rituximab + Standard Chemotherapy

rituximab cytarabine dexamethasone leucovorin calcium methotrexate procarbazine hydrochloride vincristine sulfate

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Rituximab + Standard Chemotherapy25

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Rituximab + Standard Chemotherapy64Not reported42.582Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        42.5
        upper Limit
        82
        value
        64
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
Assessed by the ECOG-ACRIN data manager based upon local review of images and data sent by the local sites. Treatment response was determined by calculating the sum of the maximal cross section in 2 separate axes using enhancing lesion(s) on CT or MRI imaging. The same imaging modality was to be used throughout assessment. Complete response was defined as the disappearance of all contrast enhancing tumor size on CT or MRI, patient was off all glucocorticoids, and resolution of all meningeal and vitreous involvement if present. Response must have lasted at least 4 weeks.
dispersion Type
95% Confidence Interval
groups
  1. description
    rituximab cytarabine dexamethasone leucovorin calcium methotrexate procarbazine hydrochloride vincristine sulfate
    id
    OG000
    title
    Rituximab + Standard Chemotherapy
param Type
NUMBER
population Description
Eligible, treated patients
reporting Status
POSTED
time Frame
For the primary endpoint, complete response will be based on disease status at three weeks post the end of therapy (week 17).
title
Complete Response Rate - Locally Reviewed
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice